JNJ

190.85

-0.66%↓

ABT

126.63

+0.17%↑

MDT

93.85

-0.53%↓

VEEV

293.38

+0.69%↑

A

148.14

+0.67%↑

JNJ

190.85

-0.66%↓

ABT

126.63

+0.17%↑

MDT

93.85

-0.53%↓

VEEV

293.38

+0.69%↑

A

148.14

+0.67%↑

JNJ

190.85

-0.66%↓

ABT

126.63

+0.17%↑

MDT

93.85

-0.53%↓

VEEV

293.38

+0.69%↑

A

148.14

+0.67%↑

JNJ

190.85

-0.66%↓

ABT

126.63

+0.17%↑

MDT

93.85

-0.53%↓

VEEV

293.38

+0.69%↑

A

148.14

+0.67%↑

JNJ

190.85

-0.66%↓

ABT

126.63

+0.17%↑

MDT

93.85

-0.53%↓

VEEV

293.38

+0.69%↑

A

148.14

+0.67%↑

Search

Guardant Health Inc

Fermé

SecteurSoins de santé

72.17 4.31

Résumé

Variation du prix de l'action

24h

Actuel

Min

69.34

Max

72.53

Chiffres clés

By Trading Economics

Revenu

-4.7M

-100M

Ventes

29M

232M

Marge bénéficiaire

-43.044

Employés

1,999

EBITDA

22M

-89M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+5.6% upside

Dividendes

By Dow Jones

Prochains Résultats

29 oct. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

3.3B

8.8B

Ouverture précédente

67.86

Clôture précédente

72.17

Sentiment de l'Actualité

By Acuity

21%

79%

45 / 371 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Guardant Health Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

23 oct. 2025, 20:49 UTC

Résultats

Correction to Thermo Fisher Article on Oct. 22

23 oct. 2025, 23:51 UTC

Market Talk

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

23 oct. 2025, 23:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23 oct. 2025, 23:49 UTC

Market Talk

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

23 oct. 2025, 23:37 UTC

Market Talk

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

23 oct. 2025, 22:58 UTC

Market Talk

Global Energy Roundup: Market Talk

23 oct. 2025, 22:57 UTC

Market Talk

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

23 oct. 2025, 22:49 UTC

Acquisitions, Fusions, Rachats

How Trump Sparked a New Era of State Capitalism -2-

23 oct. 2025, 22:49 UTC

Acquisitions, Fusions, Rachats

How Trump Sparked a New Era of State Capitalism -- Barrons.com

23 oct. 2025, 22:17 UTC

Résultats

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

23 oct. 2025, 21:41 UTC

Résultats

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

23 oct. 2025, 21:05 UTC

Résultats

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

23 oct. 2025, 20:50 UTC

Market Talk
Résultats

Tech, Media & Telecom Roundup: Market Talk

23 oct. 2025, 20:50 UTC

Market Talk
Résultats

Auto & Transport Roundup: Market Talk

23 oct. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

23 oct. 2025, 20:35 UTC

Résultats

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

23 oct. 2025, 20:28 UTC

Résultats

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

23 oct. 2025, 20:15 UTC

Market Talk
Résultats

Global Commodities Roundup: Market Talk

23 oct. 2025, 20:10 UTC

Résultats

Newmont Mining 3Q Adj EPS $1.71

23 oct. 2025, 20:10 UTC

Résultats

Newmont Mining 3Q Sales $5.52B

23 oct. 2025, 20:10 UTC

Résultats

Newmont Mining 3Q EPS $1.67

23 oct. 2025, 20:09 UTC

Résultats

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

23 oct. 2025, 20:07 UTC

Market Talk
Résultats

Global Equities Roundup: Market Talk

23 oct. 2025, 20:07 UTC

Market Talk
Résultats

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

23 oct. 2025, 20:07 UTC

Résultats

Blackstone Looks to IPOs for Investment Exits -- Update

23 oct. 2025, 20:05 UTC

Résultats

Intel 3Q Gross Margin 38.2% >INTC

23 oct. 2025, 20:04 UTC

Résultats

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

23 oct. 2025, 20:04 UTC

Résultats

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

23 oct. 2025, 20:04 UTC

Résultats

Intel: 4Q Guidance Excludes Altera >INTC

23 oct. 2025, 20:04 UTC

Résultats

Intel Sees 4Q Adj EPS 8c >INTC

Comparaison

Variation de prix

Guardant Health Inc prévision

Objectif de Prix

By TipRanks

5.6% hausse

Prévisions sur 12 Mois

Moyen 71.84 USD  5.6%

Haut 90 USD

Bas 60 USD

Basé sur 21 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

21 ratings

21

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

38.86 / 47.41Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Bullish Evidence

Sentiment

By Acuity

45 / 371Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Moyen

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat